Skip to main content
Curocell Inc. logo

Curocell Inc. — Investor Relations & Filings

Ticker · 372320 ISIN · KR7372320002 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2026-03-12 Proxy Solicitation & In…
Country KR South Korea
Listing KO 372320

About Curocell Inc.

https://curocellbtx.com/

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains information regarding the solicitation of proxies for a general meeting of shareholders, including the purpose of the meeting, details about the solicitors, and voting procedures. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Curocell. It details the date, location, agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits), and provides biographical details for the nominees. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-03-12 Korean
파생상품거래손실발생
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure regarding a 'Loss from Derivatives Transaction' (파생상품거래손실발생) filed by the company Qurocell. It details the accounting-based valuation loss related to convertible bonds, which is a specific financial event disclosure. Since it does not fit into categories like Annual Reports, Earnings Releases, or M&A, and is a specific regulatory filing required by the exchange for material financial events, it falls under the 'Regulatory Filings' category.
2026-03-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (insider holdings). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes in control.
2026-03-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory requirement for directors or major shareholders to disclose changes in their personal shareholdings (insider trading). Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2026-03-11 Korean
전환청구권행사
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Qurocell) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2026-02-24 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.